{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-029913","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.163990+00:00","generated_at":"2026-06-06T04:54:07.924445+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Spero Therapeutics Chief Legal Officer Tamara Joseph to depart March 6, 2024","bullets":["Tamara Joseph, Chief Legal Officer and Corporate Secretary, is leaving effective March 6, 2024 to pursue other interests.","Severance includes continuation of base salary for nine months totaling $356,298.75, plus prorated cash bonus of $34,266.98.","Joseph will provide consulting services on an hourly as-needed basis for nine months at $395/hour; stock options and RSUs continue vesting.","Separation and Consulting Agreement entered February 9, 2024; full terms to be filed with Form 10-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-029913","json":"https://secwatch.observer/filing/0001193125-24-029913.json","markdown":"https://secwatch.observer/filing/0001193125-24-029913.md","text":"https://secwatch.observer/filing/0001193125-24-029913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/0001193125-24-029913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/d45988d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:54:07.924445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c6956e3cd","claim":"Tamara Joseph departed as Chief Legal Officer and Corporate Secretary at Spero Therapeutics, Inc..","evidence_excerpt":"Tamara Joseph, the Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc. (the “Company”), is stepping down from that position to pursue other interests, effective as of March 6, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/0001193125-24-029913-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Chief Legal Officer and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}